Drug delivery to the spinal cord tagged with nanowire enhances neuroprotective efficacy and functional recovery following trauma to the rat spinal cord

Annals of the New York Academy of Sciences

Volumn 1122, Issue , 2007, Pages 197-218

  Sharma, Hari Shanker ^a,g   Ali, Syed F ^b   Dong, W ^c   Tian, Z Ryan ^c   Patnaik, R ^d   Patnaik, S ^d   Sharma, Aruna ^a   Boman, Arne ^e   Lek, Per ^e   Seifert, Elisabeth ^e   Lundstedt, Torbjörn ^e,f  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^c UNIVERSITY OF ARKANSAS   (United States)

^d BANARAS HINDU UNIVERSITY   (India)

^e AcurePharma AB   (Sweden)

^f UPPSALA UNIVERSITY   (Sweden)

^g NONE   (Sweden)

Author keywords

Blood spinal cord barrier; Evans blue; Functional paralysis; Nanowires, spinal cord injury; Protein tracer; Radioiodine; Spinal cord damage; Spinal cord edema

Indexed keywords

ALBUMIN; AP 173; AP 364; AP 713; EQUITHESIN; EVANS BLUE; IODINE 131; NANOWIRE; NEUROPROTECTIVE AGENT; TITANIUM DIOXIDE; UNCLASSIFIED DRUG;

ANESTHESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ATTENUATION; BEHAVIOR; BEHAVIOR DISORDER; BLOOD BRAIN BARRIER; BRAIN EDEMA; CELL DAMAGE; CENTRAL NERVOUS SYSTEM; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED STUDY; CONVALESCENCE; DRUG DELIVERY SYSTEM; DRUG EFFECT; INCISION; MALE; MOTOR PERFORMANCE; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; PATHOLOGY; RAT; SPINAL CORD; SPINAL CORD DORSAL HORN; SPINAL CORD INJURY; THERAPY EFFECT; THORACIC SPINE;

RATTUS;

EID: 36148980124     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1403.014     Document Type: Conference Paper

References (55)

1. SHARMA, H.S. 2004. Pathophysiology of the blood-spinal cord barrier in traumatic injury. In H.S. Sharma & J. Westman, Eds.: 437-518. The Blood-Spinal Cord and Brain Barriers in Health and Disease. Elsevier Academic Press. San Diego.
2. SHARMA, H.S., F. NYBERG, T. GORDH & P. ALM. 2006. Topical application of dynorphin A (1-17) antibodies attenuates neuronal nitric oxide synthase upregulation, edema formation, and cell injury following focal trauma to the rat spinal cord. Acta Neurochir. Suppl. 96: 309-315.
3. SCHWAB, M.E. & D. BARTHOLDI. Degeneration and regeneration of axons in the lesioned spinal cord. Physiol Rev. 76: 319-370.
4. KAKULAS, B.A. 2004. Neuropathology: the foundation for new treatments in spinal cord injury. Spinal Cord 42: 549-563.
5. SHARMA, H.S., Y. OLSSON & P.K. DEY. 1990. Early accumulation of serotonin in rat spinal cord subjected to traumatic injury. Relation to edema and blood flow changes. Neuroscience 36: 725-730.
6. SHARMA, H.S., Y. OLSSON, F. NYBERG & P.K. DEY. 1993. Prostaglandins modulate alterations of microvascular permeability, blood flow, edema and serotonin levels following spinal cord injury: an experimental study in the rat. Neuroscience 57: 443-449.
7. SHARMA, H.S., Y. OLSSON, S. PEARSSON & F. NYBERG. 1995. Trauma induced opening of the blood-spinal cord barrier is reduced by indomethacin, an inhibitor of prostaglandin synthesis. Experimental observations in the rat using 131I-sodium, Evans blue and lanthanum as tracers. Restor. Neurol. Neurosci. 7: 207-215.
8. SHARMA, H.S. 2004. Histamine influences the blood-spinal cord and brain barriers following injuries to the central nervous system. In H.S. Sharma & J. Westman, Eds.: 159-190. The Blood-Spinal Cord and Brain Barriers in Health and Disease. Elsevier Academic Press. San Diego.
9. SHARMA, H.S. 2006. Post-traumatic application of brain-derived neurotrophic factor and glia-derived neurotrophic factor on the rat spinal cord enhances neuroprotection and improves motor function. Acta Neurochir. Suppl. 96: 329-334.
10. EMERICH, D.F. & C.G. THANOS. 2006. The pinpoint promise of nanoparticle-based drug delivery and molecular diagnosis. Biomol. Eng. 23: 171-184.
11. SHARMA, H.S., A. SKOTTNER, T. LUNDSTEDT, et al. 2006. Neuroprotective effects of melanocortins in experimental spinal cord injury. An experimental study in the rat using topical application of compounds with varying affinity to melanocortin receptors. J. Neural Transm. 113: 463-476.
12. SHARMA, H.S. 2005. Neuroprotective effects of neurotrophins and melanocortins in spinal cord injury: an experimental study in the rat using pharmacological and morphological approaches. Ann. N. Y. Acad. Sci. 1053: 407-421.
13. SHARMA, H.S. 2005. Pathophysiology of blood-spinal cord barrier in traumatic injury and repair. Curr. Pharm. Des. 11: 1353-1389.
14. SHARMA, H.S. & P.K. DEY. 1982. Correlation of spinal cord tissue 5-HT with edema development following surgical spinal cord trauma in rats. Indian J. Physiol. Pharmacol. 26(Supplement I): 8-9.
15. SHARMA, H.S., J. WESTMAN, Y. OLSSON, et al. 1990. Increased 5-hydroxytryptamine immunoreactivity in traumatized spinal cord. An experimental study in the rat. Acta Neuropathol. (Berl) 80: 12-17.
16. SHARMA, H.S., F. NYBERG & Y. OLSSON. 1994. Topical application of dynorphin antibodies reduces edema and cell changes in traumatised rat spinal cord. Regul. Pept. (Supplement) 1: S91-S92.
17. SHARMA, H.S., Y. OLSSON, & F. NYBERG. 1995. Influence of dynorphin A antibodies on the formation of edema and cell changes in spinal cord trauma. Prog. Brain Res. 104: 401-416.
18. SHARMA, H.S., J. WESTMAN, Y. OLSSON & P. ALM. 1996. Involvement of nitric oxide in acute spinal cord injury: an immunocytochemical study using light and electron microscopy in the rat. Neurosci. Res. 24: 373-284.
19. SHARMA, H.S. A bradykinin BK2 receptor antagonist HOE-140 attenuates blood-spinal cord barrier permeability following a focal trauma to the rat spinal cord. An experimental study using Evans blue, [131]I-sodium and lanthanum tracers. Acta Neurochir. Suppl. 76: 159-163.
20. SHARMA, H.S., J. WESTMAN & F. NYBERG. 1997. Topical application of 5-HT antibodies reduces edema and cell changes following trauma of the rat spinal cord. Acta Neurochir. Suppl. 70: 155-158.
21. SHARMA, H.S., T. WINKLER, E. STALBERG, et al. 2003. Topical application of TNF-alpha antiserum attenuates spinal cord trauma induced edema formation, microvascular permeability disturbances and cell injury in the rat. Acta Neurochir. Suppl. 86: 407-413.
22. SHARMA, H.S., T. LUNDSTEDT, M. FLARDH, et al. 2003. Lowmolecularweight compounds with affinity to melanocortin receptors exert neuroprotection in spinal cord injury - an experimental study in the rat. Acta Neurochir. Suppl. 86: 399-405.
23. SHARMA, H.S., F. NYBERG, T. GORDH, et al. 2000. Neurotrophic factors influence upregulation of constitutive isoform of heme oxygenase and cellular stress response in the spinal cord following trauma. An experimental study using immunohistochemistry in the rat. Amino Acids 19: 351-361.
24. SHARMA, H.S., R.D. BADGAIYAN, P. ALM, et al. 2005. Neuroprotective effects of nitric oxide synthase inhibitors in spinal cord injury-induced pathophysiology and motor functions: an experimental study in the rat. Ann. N. Y. Acad. Sci. 1053: 422-434.
25. SHARMA, H.S., S.F. ALI, J. SCHLAGER & S. HUSSAIN. 2006. Effect of nanoparticles on the blood-brain barrier. Int. J. Neuroprotect. Neuroregen. 2: 78 p.
26. SHARMA, H.S., T. LUNDSTEDT, L. FLÄRDH, et al. 2007. Neuroprotective effects of melanocortins in CNS injury. Curr. Pharm. Des. 13: 1929-1941.
27. SHARMA, H.S. 2007. Neurotrophic factors in combination: a possible new therapeutic strategy to influence pathophysiology of spinal cord injury and repair mechanisms. Curr. Pharm. Des. 13: 1841-1874.
28. SHARMA, H.S. 2007. A select combination of neurotrophins enhances neuroprotection and functional recovery following spinal cord injury. Ann. N. Y. Acad. Sci. (in this volume).
29. KREUTER, J. 1995. Nanoparticulate systems in drug delivery and targeting. J. Drug Target. 3: 171-173.
30. ALYAUTDIN, R.N., V.E. PETROV, K. LANGER, et al. 1997. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm. Res. 14: 325-328.
31. SCHRODER, U. & B.A. SABEL. 1996. Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central analgesic effects of i.v. dalargin injections. Brain Res. 710: 121-124.
32. OLIVIER, J.C. 2005. Drug transport to brain with targeted nanoparticles. NeuroRx. 2: 108-119.
33. FRIESE, A., E. SEILLER, G. QUACK, et al. 2000. Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system. Eur. J. Pharm. Biopharm. 49: 103-109.
34. SHARMA, H.S. & A. SHARMA. 2007. Nanoparticles aggravate heat stress induced cognitive deficits, blood-brain barrier disruption, edema formation and brain pathology. Prog. Brain Res. 162: 245-276.
35. DONG, W., T. ZHANG, M. MCDONALD, et al. 2006. Biocompatible nanofiber scaffolds on metal for controlled release and cell colonization. Nanomedicine 2: 248-252.
36. SHARMA, H.S. & Y. OLSSON. Edema formation and cellular alterations following spinal cord injury in the rat and their modification with p-chlorophenylalanine. Acta Neuropathol. (Berl). 79: 604-610.
37. SHARMA, H.S., T. LUNDSTEDT, A. BOMAN, et al. 2006. A potent serotonin-modulating compound AP-267 attenuates morphine withdrawal-induced blood-brain barrier dysfunction in rats. Ann. N. Y. Acad. Sci. 1074: 482-496.
38. SHARMA, H.S., P.-O. SJÖQUIST & S.F. ALI. 2007. Drugs of abuse-induced hyperthermia, blood-brain barrier dysfunction and neurotoxicity neuroprotective effects of a new antioxidant compound H-290/51. Curr. Pharm. Des. 13: 1903-1923.
39. SHARMA, H.S., T. WINKLER, E. STALBERG, et al. 1991. Evaluation of traumatic spinal cord edema using evoked potentials recorded from the spinal epidural space. An experimental study in the rat. J. Neurol. Sci. 102: 150-162.
40. ELLIOTT, K.A.C. & H. JASPER. 1949. Measurement of experimentally induced brain swelling and shrinkage. Am. J. Physiol. 157: 122-129.
41. SHARMA, H.S. & J. CERVOS-NAVARRO. 1990. Brain oedema and cellular changes induced by acute heat stress in young rats. Acta Neurochir. Suppl. (Wien) 51: 383-386.
42. YAO, C., D.R. DOOSE, G. NOVAK & M. BIALER. 2006. Pharmacokinetics of the new antiepileptic and CNS drug RWJ-333369 following single and multiple dosing to humans. Epilepsia 47: 1822-1829.
43. VYAS, T.K., S.B. TIWARI, M.M. AMIJI. 2006. Formulation and physiological factors influencing CNS delivery upon intranasal administration. Crit. Rev. Ther. Drug Carrier Syst. 23: 319-347.
44. ASSIE, M.B., L. BARDIN, A. AUCLAIR, et al. 2007. F15063, a potential antipsychotic with dopamine D(2)/D (3) antagonist, 5-HT (1A) agonist and D (4) partial agonist properties: (IV) duration of brain D2-like receptor occupancy and antipsychotic-like activity versus plasma concentration in mice. Naunyn Schmiedebergs Arch. Pharmacol. 375: 241-250.
45. ZHAO, D., Z. FEI, W.H. ANG & P.J. DYSON. 2006. A strategy for the synthesis of transition-metal nanoparticles and their transfer between liquid phases. Small 2: 879-883.
46. KANE. R.S. & A.D. STROOCK. 2007. Nanobiotechnology: protein-nanomaterial interactions. Biotechnol. Prog. 23: 316-319.
47. IJIMA, S. 1991. Helical microtubules of graphite carbon. Nature 354: 56-58.
48. WEI, M., Z.M. QI, M. ICHIHARA, et al. 2007. Synthesis of one-dimensional sodium titanate nanostructures. J. Nanosci. Nanotechnol. 7: 1065-1068.
49. GOMMERSALL, L., I.S. SHERGILL, H.U. AHMED, et al. 2007. Nanotechnology and its relevance to the urologist. Eur. Urol. 52: 368-375.
50. CHI, B., E.S. VICTORIO & T. JIN. 2007. Synthesis of TiO2-based nanotube on Ti substrate by hydrothermal treatment. J. Nanosci. Nanotechnol. 7: 668-672.
51. SILVA, G.A., C. CZEISLER, K.L. NIECE, et al. 2004. Selective differentiation of neural progenitor cells by high-epitope density nanofibers. Science 303: 1352-1355.
52. BROKX, R.D., S.K. BISLAND & J. GARIEPY. 2002. Designing peptide-based scaffolds as drug delivery vehicles. J. Control Release 78: 115-123.
53. BETBEDER, D., S. SPERANDIO, J.P. LATAPIE, et al. 2000. Biovector nanoparticles improve antinociceptive efficacy of nasal morphine. Pharm. Res. 17: 743-748.
54. BRIGGER, I., J. MORIZET, G. AUBERT, et al. 2002. Poly(ethylene glycol)-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting. J. Pharmacol. Exp. Ther. 303: 928-936.
55. KREUTER, J. 2001. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev. 47: 65-81.